162 related articles for article (PubMed ID: 25182125)
1. Mapping knowledge translation and innovation processes in Cancer Drug Development: the case of liposomal doxorubicin.
Fajardo-Ortiz D; Duran L; Moreno L; Ochoa H; Castaño VM
J Transl Med; 2014 Sep; 12():227. PubMed ID: 25182125
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin: a guide to its use in various malignancies.
Lyseng-Williamson KA; Duggan ST; Keating GM
BioDrugs; 2013 Oct; 27(5):533-40. PubMed ID: 24018470
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.
Markman M
Expert Opin Pharmacother; 2006 Aug; 7(11):1469-74. PubMed ID: 16859430
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.
Gabizon A; Shmeeda H; Grenader T
Eur J Pharm Sci; 2012 Mar; 45(4):388-98. PubMed ID: 21933707
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin.
Petersen GH; Alzghari SK; Chee W; Sankari SS; La-Beck NM
J Control Release; 2016 Jun; 232():255-64. PubMed ID: 27108612
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin in the treatment of mycosis fungoides.
Lybaek D; Iversen L
Acta Derm Venereol; 2006; 86(6):545-7. PubMed ID: 17106606
[No Abstract] [Full Text] [Related]
7. Controlled application and removal of liposomal therapeutics: effective elimination of pegylated liposomal doxorubicin by double-filtration plasmapheresis in vitro.
Pütz G; Schmah O; Eckes J; Hug MJ; Winkler K
J Clin Apher; 2010; 25(2):54-62. PubMed ID: 20222030
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
Duggan ST; Keating GM
Drugs; 2011 Dec; 71(18):2531-58. PubMed ID: 22141391
[TBL] [Abstract][Full Text] [Related]
9. Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
Wu SK; Chiang CF; Hsu YH; Lin TH; Liou HC; Fu WM; Lin WL
Int J Nanomedicine; 2014; 9():4485-94. PubMed ID: 25278753
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.
Soloman R; Gabizon AA
Clin Lymphoma Myeloma; 2008 Feb; 8(1):21-32. PubMed ID: 18501085
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.
Molavi O; Xiong XB; Douglas D; Kneteman N; Nagata S; Pastan I; Chu Q; Lavasanifar A; Lai R
Biomaterials; 2013 Nov; 34(34):8718-8725. PubMed ID: 23942212
[TBL] [Abstract][Full Text] [Related]
13. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
14. [Liposomal doxorubicin in patients with breast cancer and concomitant cardiovascular diseases - interdisciplinary expert opinion].
Szmit S; Filipiak KJ; Litwiniuk M; Opolski G; Wysocki P; Zaborska B; Krzakowski M
Kardiol Pol; 2016; 74(9):1031-6. PubMed ID: 27654476
[TBL] [Abstract][Full Text] [Related]
15. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
[TBL] [Abstract][Full Text] [Related]
16. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.
Zhao M; Ding XF; Shen JY; Zhang XP; Ding XW; Xu B
J Zhejiang Univ Sci B; 2017 Jan.; 18(1):15-26. PubMed ID: 28070993
[TBL] [Abstract][Full Text] [Related]
17. Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report.
Wang L; Xia ZJ
Leuk Lymphoma; 2013 Nov; 54(11):2553-5. PubMed ID: 23432722
[No Abstract] [Full Text] [Related]
18. Pegylated liposomal doxorubicin consolidation therapy.
Hamm W
Oncologist; 2006; 11(7):855; author reply 855-6. PubMed ID: 16880247
[No Abstract] [Full Text] [Related]
19. [Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
Breast Cancer Group, Chinese Association for Clinical Oncologist (CACO)
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):617-623. PubMed ID: 32867451
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.
Sorenmo K; Samluk M; Clifford C; Baez J; Barrett JS; Poppenga R; Overley B; Skorupski K; Oberthaler K; Van Winkle T; Seiler G; Shofer F
J Vet Intern Med; 2007; 21(6):1347-54. PubMed ID: 18196746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
